Abiraterone Acetate Tablet
Product Images NDC 42291-024

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Abiraterone Acetate (NDC 42291-024). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avkare, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

024 12 250mg

Abiraterone Acetate Tablets, USP 250 mg oral tablets label from AvKARE. The label shows the NDC 42291-024, with a package size of 120 tablets. It includes a warning for women who are or may be pregnant not to handle the tablets without gloves. Storage instructions specify 20° to 25°C with permitted excursions and recommend keeping out of reach of children. Manufactured by AvKARE, Inc. and Amneal Pharmaceuticals of NY, LLC.*

FDA Label Image

1 (Abiraterone Acetate Tablets 1)

Chemical structure diagram of Abiraterone, the active ingredient in Abiraterone Acetate tablets. The structure shows the steroid-like framework with a pyridine ring attached, labeled with carbon, hydrogen, oxygen atoms, and bonds representing the molecular composition.*

FDA Label Image

Figure 1 (Abiraterone Acetate Tablets 2)

Kaplan-Meier survival curve comparing percent survival over time (months to death) between Abiraterone Acetate 250 mg oral tablets and placebo groups. The graph shows survival percentage on the vertical axis and time in months on the horizontal axis, with distinct curves for each treatment. Sample sizes for each group at different time points are included below the timeline.*

FDA Label Image

Figure 2 (Abiraterone Acetate Tablets 3)

A Kaplan-Meier survival curve comparing the percentage of subjects without death over months from randomization between Abiraterone Acetate and placebo groups. The y-axis shows % subjects without death, and the x-axis shows time in months up to 60. Number of subjects at risk for both groups is listed below the x-axis.*

FDA Label Image

Figure 3 (Abiraterone Acetate Tablets 4)

Kaplan-Meier survival curve comparing Abiraterone Acetate and placebo over 18 months from randomization. The y-axis represents the percentage of subjects without radiographic progression or death, while the x-axis shows months. Two lines depict the survival trends for Abiraterone Acetate and placebo groups, with sample size counts at various months listed below the x-axis.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.